key: cord-0778699-emct8b23
authors: McBane, Robert D.
title: Thromboembolism and the Pandemic
date: 2020-11-03
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.09.543
sha: 4e2c7fd75b1cfa9caaa8455df85e0fc4f8e3af67
doc_id: 778699
cord_uid: emct8b23

[Figure: see text]

Thromboembolism and the Pandemic* 

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

for the Global COVID-19 Thrombosis Collaborative Group. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Registry of arterial and venous thromboembolic complications in patients with COVID-19

Postdischarge venous thromboembolism following hospital admission with COVID-19

Dalteparin versus unfractionated heparin in critically ill patients

Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors

for the Prophylaxis for Thromboembolism in Critical Care Trial Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study

The cumulative venous thromboembolism incidence and risk factors in intensive care patient is receiving guideline recommended thromboprophylaxis

VTE incidence and risk factors in patients with severe sepsis and septic shock

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

Rivaroxaban for thromboprophylaxis in acutely ill medical patients

Extended thromboprophylaxis with betrixaban in acutely ill medical patients

for the Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

High risk for thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study